Single-agent gefitinib in patients with untreated advanced non-small-cell lung cancer and poor performance status: a Minnie Pearl Cancer Research Network Phase II Trial
| Autor: | Suzanne F. Jones, F. Anthony Greco, Howard A. Burris, David R. Spigel, James R. Rubinsak, Emily R. Burkett, Natalie R. Dickson, Melodie Thomas, Daniel C. Scullin, Joseph E. Brierre, Denise A. Yardley, John D. Hainsworth, James E. Bradof |
|---|---|
| Rok vydání: | 2005 |
| Předmět: |
Pulmonary and Respiratory Medicine
Male Cancer Research medicine.medical_specialty Lung Neoplasms medicine.medical_treatment Antineoplastic Agents Adenocarcinoma Gastroenterology Disease-Free Survival Gefitinib Quality of life Internal medicine Multicenter trial Carcinoma Non-Small-Cell Lung medicine Humans Lung cancer Aged Aged 80 and over Chemotherapy business.industry Middle Aged medicine.disease Rash respiratory tract diseases Surgery Treatment Outcome Oncology Carcinoma Squamous Cell Quality of Life Quinazolines Carcinoma Large Cell Female medicine.symptom business Progressive disease Psychomotor Performance medicine.drug |
| Zdroj: | Clinical lung cancer. 7(2) |
| ISSN: | 1525-7304 |
| Popis: | BACKGROUND: Patients with advanced non–small-cell lung cancer (NSCLC) and poor performance status (PS) are often excluded from trials. Gefitinib is a safe oral agent that may benefit these patients. PATIENTS AND METHODS: Seventy-two patients with poor PS and advanced NSCLC were enrolled onto this study of gefitinib 250 mg per day given orally until disease progression, with evaluation at 8 weeks. Eligible patients had no previous chemotherapy, an Eastern Cooperative Oncology Group PS of 2/3, and stage IIIB/IV NSCLC. Quality of life (QOL) and symptom response (SR) scores were calculated using the Functional Assessment of Cancer–Lung questionnaire. Patient characteristics included a median age of 75 years; PS of 2/3; and bronchoalveolar (n = 3), adenocarcinoma (n = 29), squamous cell (n = 21), large-cell (n = 11), and unspecified histology (n = 6). Mean treatment duration was 4 months (range, 3 days to 18 months), and median duration of follow-up was 12 months. Grade 3/4 toxicities included rash and diarrhea. RESULTS: Among 70 patients assessed for response, there were 3 partial responses (4%), 32 patients with stable disease (46%), and 18 with progressive disease (26%). Median progression-free survival (PFS) and overall survival (OS) were 3.7 months and 6.3 months, respectively. Six-month and 1-year PFS and OS rates were 35% and 21% and 50% and 24%, respectively. Eighty-two percent and 48% of patients reported improvements or no change in QOL and SR, respectively. CONCLUSION: Gefitinib demonstrates modest efficacy and is well tolerated as initial therapy in advanced NSCLC for patients with poor PS. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect